Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Chris Bushe

Showing results (11-20 of 21) with videos related to

Pageof 3
Sort By:
Journal of Psychopharmacology (Oxford, England)|November 11, 2005
Diabetes and schizophrenia 2005: are we any closer to understanding the link?Richard I G Holt, Chris Bushe, Leslie Citrome
Pharmacoepidemiology and Drug Safety|April 8, 2014
Response to Cunill et alJ Antoni Ramos-Quiroga, Pedro Lopez-Romero, Chris Bushe
Journal of Psychopharmacology (Oxford, England)|November 11, 2005
Challenges in advancing mental and physical health of patients with serious mental illnessSerdar Dursun, Timothy G Dinan, Chris Bushe, et al.
Journal of Psychopharmacology (Oxford, England)|August 16, 2008
Categorical prevalence and severity of hyperprolactinaemia in two UK cohorts of patients with severe mental illness during treatment with antipsychoticsChris Bushe, David Yeomans, Tamsin Floyd, et al.
Neuropsychiatric Disease and Treatment|February 23, 2017
A review of the efficacy of atomoxetine in the treatment of attention-deficit hyperactivity disorder in children and adult patients with common comorbiditiesDavid B Clemow, Chris Bushe, Michele Mancini, et al.
Journal of Psychopharmacology (Oxford, England)|July 19, 2014
Efficacy of atomoxetine in adults with attention deficit hyperactivity disorder: an integrated analysis of the complete database of multicenter placebo-controlled trialsPhilip Asherson, Chris Bushe, Keith Saylor, et al.
CNS Drugs|April 9, 2016
Post Hoc Analysis of Potential Predictors of Response to Atomoxetine for the Treatment of Adults with Attention-Deficit/Hyperactivity Disorder using an Integrated DatabaseChris Bushe, Esther Sobanski, David Coghill, et al.
Neuro Endocrinology Letters|May 10, 2011
Weight Gain Risk Factor assessment checklist: overview and recommendation for useTamás Treuer, John Pendlebury, Hazlin Lockman, et al.
CNS Drugs|May 27, 2016
Relationships Between Functional Outcomes and Symptomatic Improvement in Atomoxetine-Treated Adult Patients with Attention-Deficit/Hyperactivity Disorder: Post Hoc Analysis of an Integrated DatabaseKatrien De Bruyckere, Chris Bushe, Christoph Bartel, et al.
Journal of Psychopharmacology (Oxford, England)|March 24, 2016
A network meta-analysis of atomoxetine and osmotic release oral system methylphenidate in the treatment of attention-deficit/hyperactivity disorder in adult patientsChris Bushe, Kathleen Day, Victoria Reed, et al.
Pageof 3

Showing results (11-20 of 21) with videos related to

Sort By:
Pageof 3
Journal of Psychopharmacology (Oxford, England)|November 11, 2005
Diabetes and schizophrenia 2005: are we any closer to understanding the link?Richard I G Holt, Chris Bushe, Leslie Citrome
Pharmacoepidemiology and Drug Safety|April 8, 2014
Response to Cunill et alJ Antoni Ramos-Quiroga, Pedro Lopez-Romero, Chris Bushe
Journal of Psychopharmacology (Oxford, England)|November 11, 2005
Challenges in advancing mental and physical health of patients with serious mental illnessSerdar Dursun, Timothy G Dinan, Chris Bushe, et al.
Journal of Psychopharmacology (Oxford, England)|August 16, 2008
Categorical prevalence and severity of hyperprolactinaemia in two UK cohorts of patients with severe mental illness during treatment with antipsychoticsChris Bushe, David Yeomans, Tamsin Floyd, et al.
Neuropsychiatric Disease and Treatment|February 23, 2017
A review of the efficacy of atomoxetine in the treatment of attention-deficit hyperactivity disorder in children and adult patients with common comorbiditiesDavid B Clemow, Chris Bushe, Michele Mancini, et al.
Journal of Psychopharmacology (Oxford, England)|July 19, 2014
Efficacy of atomoxetine in adults with attention deficit hyperactivity disorder: an integrated analysis of the complete database of multicenter placebo-controlled trialsPhilip Asherson, Chris Bushe, Keith Saylor, et al.
CNS Drugs|April 9, 2016
Post Hoc Analysis of Potential Predictors of Response to Atomoxetine for the Treatment of Adults with Attention-Deficit/Hyperactivity Disorder using an Integrated DatabaseChris Bushe, Esther Sobanski, David Coghill, et al.
Neuro Endocrinology Letters|May 10, 2011
Weight Gain Risk Factor assessment checklist: overview and recommendation for useTamás Treuer, John Pendlebury, Hazlin Lockman, et al.
CNS Drugs|May 27, 2016
Relationships Between Functional Outcomes and Symptomatic Improvement in Atomoxetine-Treated Adult Patients with Attention-Deficit/Hyperactivity Disorder: Post Hoc Analysis of an Integrated DatabaseKatrien De Bruyckere, Chris Bushe, Christoph Bartel, et al.
Journal of Psychopharmacology (Oxford, England)|March 24, 2016
A network meta-analysis of atomoxetine and osmotic release oral system methylphenidate in the treatment of attention-deficit/hyperactivity disorder in adult patientsChris Bushe, Kathleen Day, Victoria Reed, et al.
Pageof 3